MTOR and hepatocellular carcinoma: Another study indicated that exosome released from mesenchymal stem cell-derived CAFs contains miR-199a, which can sensitize HCC cells to the treatment of doxorubicin through the mTOR signaling pathway and reverse drug resistance in patients with advanced HCC (15).